{"id":6663,"date":"2024-11-21T14:51:52","date_gmt":"2024-11-21T13:51:52","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6663"},"modified":"2025-04-28T21:52:28","modified_gmt":"2025-04-28T19:52:28","slug":"tislelizumab-plus-platinum-and-etoposide-versus-placebo-plus-platinum-and-etoposide-as-first-line-treatment-for-extensive-stage-small-cell-lung-cancer-rationale-312-a-multicenter-double-blind-pla","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/tislelizumab-plus-platinum-and-etoposide-versus-placebo-plus-platinum-and-etoposide-as-first-line-treatment-for-extensive-stage-small-cell-lung-cancer-rationale-312-a-multicenter-double-blind-pla\/","title":{"rendered":"Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage small cell lung cancer (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial\u00a0"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6663","publication","type-publication","status-publish","hentry","disease_state-small-cell-lung-cancer","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6663","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6663"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}